Active	Status	Sponsor type	Region	Phase	Filter
3 Active 0 Inactive 3 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

3 Trials

Active Trials   Industry lead sponsorIndustry collaborator

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Ohishi, Akira
ATTAIN-J, NCT05931380: A Study of Once-Daily Oral Orforglipron (LY3502970) in Japanese Adult Participants With Obesity Disease	Active, not recruiting	3	236	Japan	Orforglipron, Placebo	Eli Lilly and Company	Obesity	06/25	07/25
ACHIEVE-3, NCT06045221: A Study of Orforglipron (LY3502970) Compared With Semaglutide in Participants With Type 2 Diabetes Inadequately Controlled With Metformin	Active, not recruiting	3	1576	Japan, US, RoW	Orforglipron, LY3502970, Semaglutide	Eli Lilly and Company	Type 2 Diabetes	07/25	07/25
Kaneshiro, Mizuki
ATTAIN-J, NCT05931380: A Study of Once-Daily Oral Orforglipron (LY3502970) in Japanese Adult Participants With Obesity Disease	Active, not recruiting	3	236	Japan	Orforglipron, Placebo	Eli Lilly and Company	Obesity	06/25	07/25